A 2,400-year old bronze vessel containing soup with bones has been discovered in a tomb excavated in Xi'an, capital of northwest China's Shaanxi Province, Liu Daiyun, a Shaanxi Provincial Archeological Institute official said Saturday.
The vessel is 20 centimeters tall and has a 24.5 centimeters diameter. It contains bones soaked in liquid.
The archeologists also unearthed a bronze pot containing an odorless liquid, which may be an ancient wine, Liu said.
Experts will analyze the "bone soup" and "wine."
2010年12月13日星期一
Tomb
Chinese archeologists have unearthed a number of lacquerware and bronze ware items in a tomb in central China's Hubei Province.
The tomb may have belonged to an Eastern Zhou dynasty (770 BC- 221 BC) official who died about 2,300 years ago.
The tomb was found in Shayang County, Jingmen City. Other items found include clay sculptures and bronze basins, Huang Wenxin, a researcher at the Hubei Provincial Archeological Institute, said Saturday.
Archeologists are searching for gravestone inscriptions or bamboo slips to identity the tomb's owner.
The tomb may have belonged to an Eastern Zhou dynasty (770 BC- 221 BC) official who died about 2,300 years ago.
The tomb was found in Shayang County, Jingmen City. Other items found include clay sculptures and bronze basins, Huang Wenxin, a researcher at the Hubei Provincial Archeological Institute, said Saturday.
Archeologists are searching for gravestone inscriptions or bamboo slips to identity the tomb's owner.
2010年12月1日星期三
Asia must
Asian countries must keep up with the rapidly evolving and improving medical science, especially in specialized fields like neurosurgery, Malaysian Health Minister Liow Tiong Lai said on Monday.
"This is a worldwide phenomenon and Asian countries must also keep pace," said the minister when opening the 8th Asian Congress of Neurological Surgeons (ACNC) here on Monday.
Liow said technological advances had revolutionized the ways that doctors work and treat their patients with the emergence of new technologies that enable better visualization, earlier diagnosis and treatment of diseases.
The 8th ACNC saw the participation of more than 600 delegates from Asia and beyond. Held concurrently is the First Asian Neurosurgical Nursing Congress initiated by Malaysia.
The closing of the events is on Wednesday.
"This is a worldwide phenomenon and Asian countries must also keep pace," said the minister when opening the 8th Asian Congress of Neurological Surgeons (ACNC) here on Monday.
Liow said technological advances had revolutionized the ways that doctors work and treat their patients with the emergence of new technologies that enable better visualization, earlier diagnosis and treatment of diseases.
The 8th ACNC saw the participation of more than 600 delegates from Asia and beyond. Held concurrently is the First Asian Neurosurgical Nursing Congress initiated by Malaysia.
The closing of the events is on Wednesday.
2010年11月24日星期三
Wesley Snipes
Attorneys for Wesley Snipes are asking a judge to extend the actor's bail as he prepares for a second appeal of his three-year prison sentence, according to media reports Thursday.
U.S. District Judge William Terrell Hodges on Wednesday ordered prosecutors to respond to Snipes' motion by next Tuesday.
Snipes' bail was revoked last week by Hodges, but the judge did not set a surrender date. The actor has been free on bail while appealing his 2008 conviction for willful failure to file income tax returns.
At the time of his convictions in 2008, prosecutors said Snipes had earned 38 million U.S. dollars since 1999, but had not filed tax returns or paid any federal taxes.
The deadline for Snipes to file his next appeal -- a petition for certiorari to the U.S. Supreme Court -- is Dec. 28, although a 60-day extension is possible, according to his motion.
The 48-year-old Snipes starred in the "Blade" trilogy, "White Men Can't Jump" and other films. He has recently been in Atlantaworking on a new movie called "Master Daddy."
U.S. District Judge William Terrell Hodges on Wednesday ordered prosecutors to respond to Snipes' motion by next Tuesday.
Snipes' bail was revoked last week by Hodges, but the judge did not set a surrender date. The actor has been free on bail while appealing his 2008 conviction for willful failure to file income tax returns.
At the time of his convictions in 2008, prosecutors said Snipes had earned 38 million U.S. dollars since 1999, but had not filed tax returns or paid any federal taxes.
The deadline for Snipes to file his next appeal -- a petition for certiorari to the U.S. Supreme Court -- is Dec. 28, although a 60-day extension is possible, according to his motion.
The 48-year-old Snipes starred in the "Blade" trilogy, "White Men Can't Jump" and other films. He has recently been in Atlantaworking on a new movie called "Master Daddy."
2010年11月10日星期三
Smoking increases
Women who are current or past smokers face a greater risk of dying from breast cancer, according to a new University of California, San Francisco study published by HealthDay News on Monday.
The study involved 2,265 multi-ethnic women diagnosed with breast cancer between 1997 and 2000. Researchers examined whether smoking affected death rates from breast cancer, non-breast cancer-related causes and death from all causes.
Results showed that 164 deaths from breast cancer and 120 deaths from non-breast cancer causes occurred during an average of nine years of follow-up.
Those women who were current or past smokers also had a twofold increase in the risk of dying from non-breast cancer-related causes compared with women with breast cancer who had never smoked.
"We found that women who are current smokers or have a history of smoking had a 39 percent higher rate of dying from breast cancer, even after we took into account a wide array of known prognostic factors including clinical, socioeconomic and behavioral factors," said Assistant Professor Dejana Braithwaite from the division of cancer epidemiology, department of epidemiology and biostatistics at the university.
The analysis was also conducted to examine whether body mass index, molecular breast cancer subtype or menopausal status modified risk.
Compared with those who never smoked, women who were current or past smokers and also had a HER2-negative tumor subtype had a 61 percent increased risk of dying from breast cancer, smokers with a body mass index less than 25 kg/m2 had an 83 percent risk and postmenopausal women 47 percent.
HER2 stands for "human epidermal growth factor receptor 2" and is a protein giving higher aggressiveness in breast cancers.
"The implication of this research is that it is important for physicians to improve smoking cessation efforts, especially among women newly diagnosed with breast cancer, in order to improve breast cancer specific outcomes and overall health outcomes," Braithwaite said.
The study involved 2,265 multi-ethnic women diagnosed with breast cancer between 1997 and 2000. Researchers examined whether smoking affected death rates from breast cancer, non-breast cancer-related causes and death from all causes.
Results showed that 164 deaths from breast cancer and 120 deaths from non-breast cancer causes occurred during an average of nine years of follow-up.
Those women who were current or past smokers also had a twofold increase in the risk of dying from non-breast cancer-related causes compared with women with breast cancer who had never smoked.
"We found that women who are current smokers or have a history of smoking had a 39 percent higher rate of dying from breast cancer, even after we took into account a wide array of known prognostic factors including clinical, socioeconomic and behavioral factors," said Assistant Professor Dejana Braithwaite from the division of cancer epidemiology, department of epidemiology and biostatistics at the university.
The analysis was also conducted to examine whether body mass index, molecular breast cancer subtype or menopausal status modified risk.
Compared with those who never smoked, women who were current or past smokers and also had a HER2-negative tumor subtype had a 61 percent increased risk of dying from breast cancer, smokers with a body mass index less than 25 kg/m2 had an 83 percent risk and postmenopausal women 47 percent.
HER2 stands for "human epidermal growth factor receptor 2" and is a protein giving higher aggressiveness in breast cancers.
"The implication of this research is that it is important for physicians to improve smoking cessation efforts, especially among women newly diagnosed with breast cancer, in order to improve breast cancer specific outcomes and overall health outcomes," Braithwaite said.
2010年10月22日星期五
HIV positive teacher
A 27-year-old aspiring teacher who tested positive for HIV during a mandatory medical examination before taking a post at a government-run school moved court in Yanbian county, Sichuan province, on Wednesday, demanding the job he was promised.
"He (the petitioner) has asked county personnel and education bureaus to apologize for leaking the information that he is an HIV carrier and enroll him as a primary school teacher," said a county judge surnamed Feng.
Feng said the court will decide whether to accept or reject the case in one week.
According to Xu Xinhua, lawyer of the petitioner, Xiao Jun (not his real name), this is the first case pertaining to discrimination against an HIV carrier in terms of employment in Sichuan and the second nationwide.
Xiao Jun, who comes from a family of illiterate farmers, graduated as a music major from a teachers' college in the province in 2002. Since then, he has worked as a substitute primary school teacher and done other odd jobs to earn his bread.
In August this year, Xiao Jun passed the examination for a music teaching post in a primary school in the county seat and was asked to start work on Aug 31.
But before the date, two physical examinations organized by the county education bureau found Xiao Jun was HIV positive, following which the bureau informed him verbally that it would not offer him the teaching post.
Xiao Jun insisted he was only an HIV carrier and could work and live as any other normal person if his symptoms did not develop into AIDS.
In one negotiation, in which representatives of the county personnel department, education bureau, disciplinary committee, public security bureau and health bureau were present, the personnel and education bureaus openly announced they could not enroll Xiao Jun because he was an AIDS patient.
Xiao Jun, who is single and has no girlfriend, said he did not know how he came in contact with the deadly virus. He has sought the help of the non-profit Beijing Yirenping Center, which had found an attorney for Xiao Wu (not his real name), an HIV carrier who sued the Anqing education department in Anhui province in August for denying him a teaching post.
Center coordinator Yu Fangqiang said: "Xiao Jun's situation is the same as Xiao Wu's. The center hopes both cases can help prevent discrimination against HIV carriers."
The court in Anhui had heard Xiao Wu's case and the judgment would be delivered in December, Yu said.
"I am optimistic that both Xiao Wu and Xiao Jun will win their cases because they are supported by law."
Although Xiao Wu's is regarded as the first case pertaining to employment discrimination against an HIV carrier in China, Yu believes there are more such cases that have gone unreported.
"Many don't have the courage to speak out, for they fear the information would be leaked, resulting in more discrimination," he said.
Professor Zhou Wei of the School of Law at Sichuan University considers the prejudice against AIDS stems from ignorance and fear.
"The country's AIDS Prevention and Treatment Regulation stipulates that HIV carriers and AIDS patients have the right to marriage, employment, medical treatment and school," he said.
mymaji|xdxdxd|andywu|alwaysky|wargameyau|modiscuss|xdxdxd
"He (the petitioner) has asked county personnel and education bureaus to apologize for leaking the information that he is an HIV carrier and enroll him as a primary school teacher," said a county judge surnamed Feng.
Feng said the court will decide whether to accept or reject the case in one week.
According to Xu Xinhua, lawyer of the petitioner, Xiao Jun (not his real name), this is the first case pertaining to discrimination against an HIV carrier in terms of employment in Sichuan and the second nationwide.
Xiao Jun, who comes from a family of illiterate farmers, graduated as a music major from a teachers' college in the province in 2002. Since then, he has worked as a substitute primary school teacher and done other odd jobs to earn his bread.
In August this year, Xiao Jun passed the examination for a music teaching post in a primary school in the county seat and was asked to start work on Aug 31.
But before the date, two physical examinations organized by the county education bureau found Xiao Jun was HIV positive, following which the bureau informed him verbally that it would not offer him the teaching post.
Xiao Jun insisted he was only an HIV carrier and could work and live as any other normal person if his symptoms did not develop into AIDS.
In one negotiation, in which representatives of the county personnel department, education bureau, disciplinary committee, public security bureau and health bureau were present, the personnel and education bureaus openly announced they could not enroll Xiao Jun because he was an AIDS patient.
Xiao Jun, who is single and has no girlfriend, said he did not know how he came in contact with the deadly virus. He has sought the help of the non-profit Beijing Yirenping Center, which had found an attorney for Xiao Wu (not his real name), an HIV carrier who sued the Anqing education department in Anhui province in August for denying him a teaching post.
Center coordinator Yu Fangqiang said: "Xiao Jun's situation is the same as Xiao Wu's. The center hopes both cases can help prevent discrimination against HIV carriers."
The court in Anhui had heard Xiao Wu's case and the judgment would be delivered in December, Yu said.
"I am optimistic that both Xiao Wu and Xiao Jun will win their cases because they are supported by law."
Although Xiao Wu's is regarded as the first case pertaining to employment discrimination against an HIV carrier in China, Yu believes there are more such cases that have gone unreported.
"Many don't have the courage to speak out, for they fear the information would be leaked, resulting in more discrimination," he said.
Professor Zhou Wei of the School of Law at Sichuan University considers the prejudice against AIDS stems from ignorance and fear.
"The country's AIDS Prevention and Treatment Regulation stipulates that HIV carriers and AIDS patients have the right to marriage, employment, medical treatment and school," he said.
mymaji|xdxdxd|andywu|alwaysky|wargameyau|modiscuss|xdxdxd
2010年9月27日星期一
Diabetes drug Avandia
Shanghai officials are to closely monitor adverse reactions to an anti-diabetes drug following concerns over the risk of heart disease.
The use of Avandia has been significantly restricted in the United States and sales in Europe are being suspended.
Shanghai's Food and Drug Administration said it would be cooperating with local health authorities to watch out for any problems in the city.
It asks GlaxoSmithKline, the drug's producer, to collect and report on any cases of adverse reactions in the city.
The US FDA restricts the use of Avandia to patients who can't control their diabetes with any other medicine or to current users who are benefiting from the drug.
Last Thursday, the European Medicines Agency recommended suspension of marketing authorization for Avandia and another two GlaxoSmithKline anti-diabetes drugs - Avandamet and Avaglim - with the same ingredient, rosiglitazone. These medicines will stop being available in Europe within the next few months, the agency said.
Dr Jia Weiping, director of the Shanghai Diabetes Institute, said the moves had aroused the concern of the State Food and Drug Administration, which will meet today to discuss the drug's use and adverse reaction supervision across the country.
"Local patients shouldn't panic about the news of Avandia, since its dosage for Chinese patients is much lower than that for US and European patients," Jia said. "In the West, the drug is prescribed by general physicians while the drug in China is used by specialists after careful consideration of the patient's medical history and is not used for patients with cardiovascular problems."
She said Avandia was a popular diabetes drug in China and there had been no reports of serious side effects so far.
GlaxoSmithKline said it had stopped marketing Avandia in all countries including China after regulators withdrew the product in Europe and restricted its use in the US. The British drug maker had notified China's FDA of the latest situation. It will also release a notice to patients.
"We have not received any adverse reaction reports from Chinese patients yet and we suggest patients do not stop taking the medicine before seeking advice from doctors," said a GlaxoSmithKline official.
manage Office Office well health live school
The use of Avandia has been significantly restricted in the United States and sales in Europe are being suspended.
Shanghai's Food and Drug Administration said it would be cooperating with local health authorities to watch out for any problems in the city.
It asks GlaxoSmithKline, the drug's producer, to collect and report on any cases of adverse reactions in the city.
The US FDA restricts the use of Avandia to patients who can't control their diabetes with any other medicine or to current users who are benefiting from the drug.
Last Thursday, the European Medicines Agency recommended suspension of marketing authorization for Avandia and another two GlaxoSmithKline anti-diabetes drugs - Avandamet and Avaglim - with the same ingredient, rosiglitazone. These medicines will stop being available in Europe within the next few months, the agency said.
Dr Jia Weiping, director of the Shanghai Diabetes Institute, said the moves had aroused the concern of the State Food and Drug Administration, which will meet today to discuss the drug's use and adverse reaction supervision across the country.
"Local patients shouldn't panic about the news of Avandia, since its dosage for Chinese patients is much lower than that for US and European patients," Jia said. "In the West, the drug is prescribed by general physicians while the drug in China is used by specialists after careful consideration of the patient's medical history and is not used for patients with cardiovascular problems."
She said Avandia was a popular diabetes drug in China and there had been no reports of serious side effects so far.
GlaxoSmithKline said it had stopped marketing Avandia in all countries including China after regulators withdrew the product in Europe and restricted its use in the US. The British drug maker had notified China's FDA of the latest situation. It will also release a notice to patients.
"We have not received any adverse reaction reports from Chinese patients yet and we suggest patients do not stop taking the medicine before seeking advice from doctors," said a GlaxoSmithKline official.
manage Office Office well health live school
订阅：
博文 (Atom)